Tweetable abstract The US Food and Drug Administration has agreed to review an application seeking approval of the activin signalling inhibitor sotatercept as a treatment for adults with pulmonary arterial hypertensionhttps://bit.ly/46zBDPS
No takes yet. Share an insight, caveat, or question.
Marc Humbert (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: